Imaging Acetadote Metabolism in Glioblastoma

Part of paid clinical trials in Dallas, Texas.

Sponsor
University of Texas Southwestern Medical Center
Study ID
NCT07387666
Phase
EARLY_PHASE1
Status
Recruiting

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Acetadote — DRUG
    Acetadote 150 mg/kg in 500 cc 5% dextrose IV over 1 hour

Study Details

This goal of this clinical trial is to evaluate how Acetadote affects metabolism in patients with glioblastoma. Drugs like Acetadote, which affect the level of damage in a cell (oxidative stress), may impact brain tumor metabolism and slow the growth of brain tumors. The investigators are evaluating how Acetadote affects glioblastoma metabolism by using MRI-based methods and by determining the changes in metabolism in brain tumor tissue resected from patients with a new diagnosis of glioblastoma.

Key Dates

Start date
Jun 18, 2026
Status verified
Jun 2026
Primary completion
Jul 1, 2027
Completion
Jul 1, 2028

Study Design

Enrollment
10 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Acetadote 150 mg/kg IV
    Acetadote will be administered twice during this study: first before undergoing magnetic resonance spectroscopy (MRS) on Day 1 and second before undergoing surgical resection, which will take place between Days 2-21. Acetadote will be administered at a dose of 150 mg/kg IV over 60 minutes.

Primary Outcome Measure

To determine the effect of Acetadote on glioblastoma metabolism as measured by MRS. [ Time Frame: Day 1 and up to 21 days from Day 1 ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
University of Texas Southwestern Medical CenterDallasTexas75390
Omar Raslan, MBBCH, MPH, CCRP
214-648-7097
Evan Noch, MD, PhD (PRINCIPAL_INVESTIGATOR)

Find similar trials in Dallas, TX

By condition

Related Studies